TWM
LGND icon

Tripletail Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tripletail Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-710
Closed -$130K – 264
2025
Q4 		$130K Hold
710
– – 0.16% 97
2025
Q3 		$129K Buy
+710
New +$106K 0.15% 100

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Tripletail Wealth Management's LGND Position: Q1 2026 in Review

Tripletail Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 710 shares — an estimated $130K sold.

Tripletail Wealth Management first reported a position in LGND in Q3 2025 and held it in 2 quarters. The position peaked at $130K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Tripletail Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Tripletail Wealth Management sold 710 Ligand Pharmaceuticals shares in Q1 2026, an estimated $130K.
  • Tripletail Wealth Management first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Tripletail Wealth Management's Ligand Pharmaceuticals position peaked at $130K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Tripletail Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.